[{"nid":"38","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/vaccin-contre-covid-19-particule-pseudo-virale-du-coronavirus-ppvco\/details-produit","title":"Vaccin contre la COVID-19 Particule pseudo-virale du coronavirus (PPVCo) ","brand_name":"Vaccin contre la COVID-19 Particule pseudo-virale du coronavirus (PPVCo) ","ingredient":"particule pseudo-virale du coronavirus [PPVCo]","company_name":"Medicago Inc","field_product_type":"Vaccin","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"38","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/coronavirus-particle-covlp-covid-19-vaccine\/product-details","title":"Coronavirus-like Particle (CoVLP) COVID-19 Vaccine","brand_name":"Coronavirus-like Particle (CoVLP) COVID-19 Vaccine","ingredient":"coronavirus-like particle [CoVLP]","company_name":"Medicago Inc","field_product_type":"Vaccine","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"36","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/sotrovimab\/details-produit","title":"Sotrovimab (sotrovimab)","brand_name":"Sotrovimab","ingredient":"sotrovimab","company_name":"GlaxoSmithKline Inc","field_product_type":"Traitement","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"36","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/sotrovimab\/product-details","title":"Sotrovimab (sotrovimab)","brand_name":"Sotrovimab","ingredient":"sotrovimab","company_name":"GlaxoSmithKline Inc","field_product_type":"Treatment","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"35","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/leronlimab\/details-produit","title":"Leronlimab (leronlimab)","brand_name":"Leronlimab","ingredient":"leronlimab","company_name":"CytoDyn, Inc.","field_product_type":"Traitement","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"35","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/leronlimab\/product-details","title":"Leronlimab (leronlimab)","brand_name":"Leronlimab","ingredient":"leronlimab","company_name":"CytoDyn, Inc.","field_product_type":"Treatment","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"34","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/casirivimab-et-imdevimab\/details-produit","title":"Casirivimab (casirivimab) et imdevimab (imdevimab)","brand_name":"Casirivimab et imdevimab","ingredient":"casirivimab \/ imdevimab","company_name":"Hoffmann-La Roche Limited","field_product_type":"Traitement","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"34","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/casirivimab-and-imdevimab\/product-details","title":"Casirivimab (casirivimab) and imdevimab (imdevimab)","brand_name":"Casirivimab and imdevimab","ingredient":"casirivimab \/ imdevimab","company_name":"Hoffmann-La Roche Limited","field_product_type":"Treatment","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"32","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/bamlanivimab-et-etesevimab\/details-produit","title":"Bamlanivimab (LY-CoV555) et etesevimab (LY-CoV016)","brand_name":"Bamlanivimab et etesevimab","ingredient":"LY-CoV555\/LY-CoV016","company_name":"Eli Lilly Canada Inc","field_product_type":"Traitement","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"32","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/bamlanivimab-and-etesevimab\/product-details","title":"Bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)","brand_name":"Bamlanivimab and etesevimab","ingredient":"LY-CoV555 \/ LY-CoV016","company_name":"Eli Lilly Canada Inc","field_product_type":"Treatment","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"31","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/vaccin-novavax-contre-covid-19\/details-produit","title":"Vaccin de Novavax contre la COVID-19 (NVX-CoV2373)","brand_name":"Vaccin de Novavax contre la COVID-19","ingredient":"NVX-CoV2373","company_name":"Novavax Inc","field_product_type":"Vaccin","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"31","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/novavax-covid-19-vaccine\/product-details","title":"Novavax COVID-19 Vaccine (NVX-CoV2373)","brand_name":"Novavax COVID-19 Vaccine","ingredient":"NVX-CoV2373","company_name":"Novavax Inc","field_product_type":"Vaccine","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"29","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/covishield\/details-produit","title":"COVISHIELD (ChAdOx1-S [recombinant])","brand_name":"COVISHIELD","ingredient":"ChAdOx1-S [recombinant]","company_name":"Verity Pharmaceuticals Inc\/Serum Institute of India (en partenariat avec AstraZeneca Canada Inc)","field_product_type":"Vaccin","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"2021-02-26","language":"Fran\u00e7ais","resources":[{"id":"88","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/covishield-fr.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"89","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-26","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EPartie II : Renseignements scientifiques\u003C\/li\u003E\n\t\u003Cli\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-pm-fr.pdf","text":"Monographie de produit"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"90","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-01","description":"\u003Cp\u003E\u00c9tiquettes de r\u00e9f\u00e9rence canadiennes pour les \u00e9tiquettes des flacons et des cartons. Ces \u00e9tiquettes fournissent des informations sp\u00e9cifiques au Canada en fran\u00e7ais et en anglais et peuvent \u00eatre utilis\u00e9es comme r\u00e9f\u00e9rence jusqu\u0027\u00e0 ce que le fabricant les adopte sur le flacon et le carton du produit sp\u00e9cifique au Canada.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-etiquette.pdf","text":"\u00c9tiquettes de r\u00e9f\u00e9rence canadiennes"},"various_dates":"False"},{"id":"91","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-01","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement initial en vaccins.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-etiquette-mondial.pdf","text":"\u00c9tiquette provisioire du produit"},"various_dates":"False"},{"id":"92","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-02-26","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00773","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"various_dates":"False"},{"id":"93","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-26","description":"\u003Cp\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00520","text":"Sommaire des motifs de d\u00e9cision"},"updated_date":"2021-03-26","various_dates":"False"},{"id":"125","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-19","description":"\u003Cp\u003EUn resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9 compl\u00e8te d\u0027autres informations li\u00e9es \u00e0 l\u0027innocuit\u00e9 afin d\u0027aider les Canadiens \u00e0 prendre des d\u00e9cisions \u00e9clair\u00e9es au sujet du l\u0027utilisation des produits de sant\u00e9. Chaque r\u00e9sum\u00e9 pr\u00e9sente les donn\u00e9es \u00e9valu\u00e9es dans le cadre de l\u2019examen de Sant\u00e9 Canada, les conclusions et les mesures prises par Sant\u00e9 Canada, le cas \u00e9ch\u00e9ant.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/resume-examen-innocuite-detail.html?linkID=SSR00265","text":"Resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9"},"various_dates":"False"},{"id":"94","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00520","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"updated_date":"2021-04-19","various_dates":"False"},{"id":"96","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/","text":"Effets secondaires suivant l\u2019immunisation"},"various_dates":"True"},{"id":"97","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"","text":"Plan de gestion des risques"},"various_dates":"False"},{"id":"98","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-06-30","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"99","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-30","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit. Le statut des conditions sera mis \u00e0 jour sur une base r\u00e9guli\u00e8re.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-autorisation.pdf","text":"Conditions de l\u2019autorisation"},"updated_date":"2021-04-30","various_dates":"False"},{"id":"100","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis publics et les communications des risques li\u00e9s aux produits de sant\u00e9 sont deux moyens par lesquels Sant\u00e9 Canada communique les questions de s\u00e9curit\u00e9. Ils sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22COVISHIELD%22%20OU%20%22ChAdOx1-S%20%5Brecombinant%5D%22","text":"Avis publics et communications des risques"},"various_dates":"True"}]},{"nid":"29","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/covishield\/product-details","title":"COVISHIELD (ChAdOx1-S [recombinant])","brand_name":"COVISHIELD ","ingredient":"ChAdOx1-S [recombinant]","company_name":"Verity Pharmaceuticals Inc\/Serum Institute of India (in partnership with AstraZeneca Canada Inc)","field_product_type":"Vaccine","status":"Authorized By Interim Order","date_of_approval":"2021-02-26","language":"English","resources":[{"id":"88","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/covishield-en.html","text":"Consumer Information"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"89","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-26","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-pm-en.pdf","text":"Product Monograph"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"90","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-01","description":"\u003Cp\u003EThe Canadian reference labels for the vial and carton labels. These labels provide information specific to Canada in both French and English and can be used as reference until the manufacturer implements them on the Canadian-specific product vial and carton.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-label.pdf","text":"Canadian Reference Label"},"various_dates":"False"},{"id":"91","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-01","description":"\u003Cp\u003EVial and carton labels for vaccine with English-only labelling. These labels are used for the initial supply of vaccine.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-global-label.pdf","text":"Interim Product Label"},"various_dates":"False"},{"id":"92","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-02-26","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00773","text":"Regulatory Decision Summary"},"various_dates":"False"},{"id":"93","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-26","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00520","text":"Summary Basis of Decision"},"updated_date":"2021-03-26","various_dates":"False"},{"id":"125","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-19","description":"\u003Cp\u003EA Summary Safety Review complements other safety related information to help Canadians make informed decisions about their use of health products. Each summary outlines what was assessed in Health Canada\u2019s review, what was found and what action was taken by Health Canada, if any.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-safety-review-detail.html?linkID=SSR00265","text":"Summary Safety Review"},"various_dates":"False"},{"id":"94","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00520","text":"Post-Authorization Activity Table (PAAT) "},"updated_date":"2021-04-19","various_dates":"False"},{"id":"96","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/","text":"Adverse Events Following Immunization"},"various_dates":"True"},{"id":"97","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003EThe Company\u2019s Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"","text":"Risk Management Plan"},"various_dates":"False"},{"id":"98","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-06-30","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Clinical Information"},"various_dates":"False"},{"id":"99","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-30","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product. The status of the terms and conditions will be updated on a regular basis.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covishield-authorisation.pdf","text":"Authorization Terms \u0026 Conditions"},"updated_date":"2021-04-30","various_dates":"False"},{"id":"100","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EPublic Advisories and Health Product Risk Communications are two ways that Health Canada communicates safety issues. They are published when Health Canada has important updates or other information to share about the product, such as new approvals, information on shortages, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories and risk communications that Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22COVISHIELD%22%20OR%20%22ChAdOx1-S%20%5Brecombinant%5D%22","text":"Public Advisories and Risk Communications"},"various_dates":"True"}]},{"nid":"28","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/vaccin-astrazeneca-contre-covid-19\/details-produit","title":"Vaccin d\u0026#039;AstraZeneca contre la COVID-19 (ChAdOx1-S [recombinant])","brand_name":"Vaccin d\u0026#039;AstraZeneca contre la COVID-19","ingredient":"ChAdOx1-S [recombinant]","company_name":"AstraZeneca Canada Inc","field_product_type":"Vaccin","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"2021-02-26","language":"Fran\u00e7ais","resources":[{"id":"74","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/vaccin-astrazeneca-contre-covid-19-fr.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"75","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-26","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EPartie II : Renseignements scientifiques\u003C\/li\u003E\n\t\u003Cli\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-astrazeneca-contre-covid-19-pm-fr.pdf","text":"Monographie de produit"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"87","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-01","description":"\u003Cp\u003E\u00c9tiquettes de r\u00e9f\u00e9rence canadiennes pour les \u00e9tiquettes des flacons et des cartons. Ces \u00e9tiquettes fournissent des informations sp\u00e9cifiques au Canada en fran\u00e7ais et en anglais et peuvent \u00eatre utilis\u00e9es comme r\u00e9f\u00e9rence jusqu\u0027\u00e0 ce que le fabricant les adopte sur le flacon et le carton du produit sp\u00e9cifique au Canada.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-astrazeneca-contre-covid-19-etiquette.pdf","text":"\u00c9tiquettes de r\u00e9f\u00e9rence canadiennes"},"various_dates":"False"},{"id":"76","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-05-11","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement en vaccins provenant de COVAX.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-astrazeneca-contre-covid-19-etiquette-mondial.pdf","text":"\u00c9tiquette provisioire du produit (approvisionnement de COVAX)"},"updated_date":"2021-05-11","various_dates":"False"},{"id":"122","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-04-01","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement initial en vaccins provenant des \u00c9tats unis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-astrazeneca-contre-covid-19-usa-etiquette.pdf","text":"\u00c9tiquette provisioire du produit (approvisionnement des \u00c9tats unis)"},"various_dates":"False"},{"id":"77","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-02-26","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/vaccin-covid.canada.ca\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00772","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"various_dates":"False"},{"id":"78","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-26","description":"\u003Cp\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00519","text":"Sommaire des motifs de d\u00e9cision"},"updated_date":"2021-03-26","various_dates":"False"},{"id":"124","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-19","description":"\u003Cp\u003EUn resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9 compl\u00e8te d\u0027autres informations li\u00e9es \u00e0 l\u0027innocuit\u00e9 afin d\u0027aider les Canadiens \u00e0 prendre des d\u00e9cisions \u00e9clair\u00e9es au sujet du l\u0027utilisation des produits de sant\u00e9. Chaque r\u00e9sum\u00e9 pr\u00e9sente les donn\u00e9es \u00e9valu\u00e9es dans le cadre de l\u2019examen de Sant\u00e9 Canada, les conclusions et les mesures prises par Sant\u00e9 Canada, le cas \u00e9ch\u00e9ant.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/resume-examen-innocuite-detail.html?linkID=SSR00265","text":"Resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9"},"various_dates":"False"},{"id":"79","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00519","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"updated_date":"2021-04-19","various_dates":"False"},{"id":"81","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/","text":"Effets secondaires suivant l\u2019immunisation"},"various_dates":"True"},{"id":"82","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"","text":"Plan de gestion des risques"},"various_dates":"False"},{"id":"83","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-06-30","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"84","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-30","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit. Le statut des conditions sera mis \u00e0 jour sur une base r\u00e9guli\u00e8re.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-astrazeneca-contre-covid-19-autorisation.pdf","text":"Conditions de l\u2019autorisation"},"updated_date":"2021-04-30","various_dates":"False"},{"id":"85","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis publics et les communications des risques li\u00e9s aux produits de sant\u00e9 sont deux moyens par lesquels Sant\u00e9 Canada communique les questions de s\u00e9curit\u00e9. Ils sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Vaccin%20AstaZeneca%20contre%20COVID-19%22%20OU%20%22ChAdOx1-S%20%5Brecombinant%5D%22%20OU%20%22AstraZeneca%20et%20COVISHIELD%22%20OU%20%22vaccin%20contre%20la%20COVID-19%20d%27Astrazeneca%22","text":"Avis publics et communications des risques"},"various_dates":"True"}]},{"nid":"28","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/astrazeneca-covid-19-vaccine\/product-details","title":"AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant])","brand_name":"AstraZeneca COVID-19 Vaccine","ingredient":"ChAdOx1-S [recombinant]","company_name":"AstraZeneca Canada Inc","field_product_type":"Vaccine","status":"Authorized By Interim Order","date_of_approval":"2021-02-26","language":"English","resources":[{"id":"74","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/astrazeneca-covid-19-vaccine-en.html","text":"Consumer Information"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"75","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-26","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/astrazeneca-covid-19-vaccine-pm-en.pdf","text":"Product Monograph"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"87","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-01","description":"\u003Cp\u003EThe Canadian reference labels for the vial and carton labels. These labels provide information specific to Canada in both French and English and can be used as reference until the manufacturer implements them on the Canadian-specific product vial and carton.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/astrazeneca-covid-19-vaccine-label.pdf","text":"Canadian Reference Label"},"various_dates":"False"},{"id":"76","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-05-11","description":"\u003Cp\u003EVial and carton labels for vaccine with English-only labelling. These labels are used for the supply of vaccine that is coming from COVAX.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/astrazeneca-covid-19-vaccine-global-label.pdf","text":"Interim Product Label (COVAX supply)"},"updated_date":"2021-05-11","various_dates":"False"},{"id":"122","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-04-01","description":"\u003Cp\u003EVial and carton labels for vaccine with English-only labelling. These labels are used for the initial supply of vaccine that is coming from the United States.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/astrazeneca-covid-19-vaccine-usa-label.pdf","text":"Interim Product Label (United States supply)"},"various_dates":"False"},{"id":"77","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-02-26","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00772","text":"Regulatory Decision Summary"},"various_dates":"False"},{"id":"78","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-26","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00519","text":"Summary Basis of Decision"},"updated_date":"2021-03-26","various_dates":"False"},{"id":"124","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-19","description":"\u003Cp\u003EA Summary Safety Review complements other safety related information to help Canadians make informed decisions about their use of health products. Each summary outlines what was assessed in Health Canada\u2019s review, what was found and what action was taken by Health Canada, if any.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-safety-review-detail.html?linkID=SSR00265","text":"Summary Safety Review"},"various_dates":"False"},{"id":"79","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-06-15","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00519","text":"Post-Authorization Activity Table (PAAT) "},"updated_date":"2021-06-15","various_dates":"False"},{"id":"81","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/","text":"Adverse Events Following Immunization"},"various_dates":"True"},{"id":"82","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003EThe Company\u2019s Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"","text":"Risk Management Plan"},"various_dates":"False"},{"id":"83","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-06-30","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Clinical Information"},"various_dates":"False"},{"id":"84","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-30","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product. The status of the terms and conditions will be updated on a regular basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/astrazeneca-covid-19-vaccine-authorisation.pdf","text":"Authorization Terms \u0026 Conditions"},"updated_date":"2021-04-30","various_dates":"False"},{"id":"85","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EPublic Advisories and Health Product Risk Communications are two ways that Health Canada communicates safety issues. They are published when Health Canada has important updates or other information to share about the product, such as new approvals, information on shortages, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories and risk communications that Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22AstraZeneca%20COVID-19%20Vaccine%22%20OR%20%22ChAdOx1%20%5Brecombinant%5D%22OR%20%22AstraZeneca%20and%20COVISHIELD%20COVID-19%20vaccines%22","text":"Public Advisories and Risk Communications"},"various_dates":"True"}]},{"nid":"27","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/janssen-covid-19-vaccine\/details-produit","title":"Janssen COVID-19 Vaccine","brand_name":"Janssen COVID-19 Vaccine","ingredient":"Ad26.COV2.S [recombinant]","company_name":"Janssen Inc","field_product_type":"Vaccin","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"2021-03-05","language":"Fran\u00e7ais","resources":[{"id":"105","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/janssen-covid-19-vaccine-fr.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"103","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-26","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EPartie II : Renseignements scientifiques\u003C\/li\u003E\n\t\u003Cli\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-pm-fr.pdf","text":"Monographie de produit"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"108","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-08","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement initial en vaccins provenant des \u00c9tats-Unis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-etiquette.pdf","text":"\u00c9tiquette provisoire du produit (approvisionnement des \u00c9tats-Unis)"},"various_dates":"False"},{"id":"126","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement initial en vaccins provenant de l\u2019ext\u00e9rieur des \u00c9tats-Unis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-etiquette-mondial.pdf","text":"\u00c9tiquette provisoire du produit -approvisionnement de l\u2019ext\u00e9rieur des \u00c9tats-Unis"},"various_dates":"False"},{"id":"106","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-03-12","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00779","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"updated_date":"2021-03-12","various_dates":"False"},{"id":"109","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00522","text":"Sommaire des motifs de d\u00e9cision"},"various_dates":"False"},{"id":"127","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-05-04","description":"\u003Cp\u003EUn resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9 compl\u00e8te d\u0027autres informations li\u00e9es \u00e0 l\u0027innocuit\u00e9 afin d\u0027aider les Canadiens \u00e0 prendre des d\u00e9cisions \u00e9clair\u00e9es au sujet du l\u0027utilisation des produits de sant\u00e9. Chaque r\u00e9sum\u00e9 pr\u00e9sente les donn\u00e9es \u00e9valu\u00e9es dans le cadre de l\u2019examen de Sant\u00e9 Canada, les conclusions et les mesures prises par Sant\u00e9 Canada, le cas \u00e9ch\u00e9ant.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/resume-examen-innocuite-detail.html?linkID=SSR00266","text":"Resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9"},"various_dates":"False"},{"id":"110","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00522","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"various_dates":"False"},{"id":"112","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Effets secondaires suivant l\u2019immunisation"},"various_dates":"False"},{"id":"113","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"","text":"Plan de gestion des risques"},"various_dates":"False"},{"id":"114","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-06-30","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"107","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-14","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit. Le statut des conditions sera mis \u00e0 jour sur une base r\u00e9guli\u00e8re.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-autorisation.pdf","text":"Conditions de l\u2019autorisation"},"updated_date":"2021-05-14","various_dates":"False"},{"id":"115","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis publics et les communications des risques li\u00e9s aux produits de sant\u00e9 sont deux moyens par lesquels Sant\u00e9 Canada communique les questions de s\u00e9curit\u00e9. Ils sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Janssen%20COVID-19%20Vaccine%22%20OU%20%22AD26.COV2.S%20%28recombinant%29%22","text":"Avis publics et communications des risques"},"various_dates":"True"},{"id":"131","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-05-11","description":"\u003Cp\u003EUn guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-etapes-administration.pdf","text":"Conservation et administration"},"various_dates":"False"}]},{"nid":"27","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/janssen-covid-19-vaccine\/product-details","title":"Janssen COVID-19 Vaccine","brand_name":"Janssen COVID-19 Vaccine","ingredient":"Ad26.COV2.S [recombinant]","company_name":"Janssen Inc","field_product_type":"Vaccine","status":"Authorized By Interim Order","date_of_approval":"2021-03-05","language":"English","resources":[{"id":"105","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/janssen-covid-19-vaccine-en.html","text":"Consumer Information"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"103","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-26","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-pm-en.pdf","text":"Product Monograph"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"108","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-08","description":"\u003Cp\u003EVial and carton labels for vaccine with English-only labelling. These labels are used for the initial supply of vaccine coming from the United States.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-label.pdf","text":"Interim Product Label (United States supply)"},"various_dates":"False"},{"id":"126","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003EVial and carton labels for vaccine with English-only labelling. These labels are used for the initial supply of vaccine coming from manufacturing locations other than the United States.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-global-label.pdf","text":"Interim Product Label  (non-United States supply)"},"various_dates":"False"},{"id":"106","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-03-12","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00779","text":"Regulatory Decision Summary"},"updated_date":"2021-03-12","various_dates":"False"},{"id":"109","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00522","text":"Summary Basis of Decision"},"various_dates":"False"},{"id":"127","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-05-04","description":"\u003Cp\u003EA Summary Safety Review complements other safety related information to help Canadians make informed decisions about their use of health products. Each summary outlines what was assessed in Health Canada\u2019s review, what was found and what action was taken by Health Canada, if any.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-safety-review-detail.html?linkID=SSR00266","text":"Summary Safety Review"},"various_dates":"False"},{"id":"110","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00522","text":"Post-Authorization Activity Table (PAAT)"},"various_dates":"False"},{"id":"112","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Adverse Events Following Immunization"},"various_dates":"False"},{"id":"113","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"description":"\u003Cp\u003EThe Company\u2019s Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"","text":"Risk Management Plan"},"various_dates":"False"},{"id":"114","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-06-30","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"","text":"Clinical Information"},"various_dates":"False"},{"id":"107","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-14","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product. The status of the terms and conditions will be updated on a regular basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-authorisation.pdf","text":"Authorization Terms \u0026 Conditions"},"updated_date":"2021-05-14","various_dates":"False"},{"id":"115","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EPublic Advisories and Health Product Risk Communications are two ways that Health Canada communicates safety issues. They are published when Health Canada has important updates or other information to share about the product, such as new approvals, information on shortages, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories and risk communications that Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Janssen%20COVID-19%20Vaccine%22%20OR%20%22AD26.COV2.S%20%28recombinant%29%22","text":"Public Advisories and Risk Communications"},"various_dates":"True"},{"id":"131","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-05-11","description":"\u003Cp\u003EA guide to proper storage, handling, and administration of the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/janssen-covid-19-vaccine-storage-administration.pdf","text":"Storage and Administration"},"various_dates":"False"}]},{"nid":"18","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/colchicine\/details-produit","title":"Colchicine","brand_name":"Colchicine","ingredient":"colchicine","company_name":"Pendopharm Division of Pharmascience Inc","field_product_type":"Traitement","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"18","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/colchicine\/product-details","title":"Colchicine","brand_name":"Colchicine","ingredient":"colchicine","company_name":"Pendopharm Division of Pharmascience Inc","field_product_type":"Treatment","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"17","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/favipiravir\/details-produit","title":"Favipiravir (favipiravir)","brand_name":"Favipiravir","ingredient":"favipiravir","company_name":"Dr Reddys Laboratories Ltd","field_product_type":"Traitement","status":"En cours d\u2019examen","date_of_approval":null,"language":"Fran\u00e7ais","resources":[]},{"nid":"17","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/favipiravir\/product-details","title":"Favipiravir (favipiravir)","brand_name":"Favipiravir","ingredient":"favipiravir","company_name":"Dr Reddys Laboratories Ltd","field_product_type":"Treatment","status":"Under review","date_of_approval":null,"language":"English","resources":[]},{"nid":"16","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/vaccin-contre-covid-19-pfizer-biontech\/details-produit","title":"Vaccin contre la COVID-19 de Pfizer-BioNTech (tozinam\u00e9ran)","brand_name":"Vaccin contre la COVID-19 de Pfizer-BioNTech","ingredient":"tozinam\u00e9ran","company_name":"BioNTech Manufacturing GmbH","field_product_type":"Vaccin","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"2020-12-09","language":"Fran\u00e7ais","resources":[{"id":"27","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-05-05","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/vaccin-contre-la-covid-19-de-pfizer-biontech.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-05-05","various_dates":"False"},{"id":"28","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-05","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-pm1.pdf","text":"Monographie de produit"},"updated_date":"2021-05-05","various_dates":"False"},{"id":"40","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-09","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin contre la COVID-19 de Pfizer-BioNTech. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement initial en vaccins.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-etiquette.pdf","text":"\u00c9tiquette provisioire du produit"},"various_dates":"False"},{"id":"29","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-12-09","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00730","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"various_dates":"False"},{"id":"128","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-05-05","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00802","text":"Sommaire de d\u00e9cision r\u00e9glementaire (12 \u00e0 15 ans)"},"various_dates":"False"},{"id":"30","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/span\u003E\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00510","text":"Sommaire des motifs de d\u00e9cision"},"updated_date":"2021-03-19","various_dates":"False"},{"id":"70","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00510","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"updated_date":"2021-04-19","various_dates":"False"},{"id":"67","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/","text":"Effets secondaires suivant l\u2019immunisation"},"various_dates":"True"},{"id":"35","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-02-19","description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003EEn cliquant sur le lien, vous acc\u00e9dez \u00e0 un r\u00e9sum\u00e9 du plan de gestion des risque. Vous pouvez obtenir la version la plus r\u00e9cente (disponible uniquement dans la langue dans laquelle elle a \u00e9t\u00e9 soumise) en posant une demande par courriel \u00e0 \u003Ca href=\u0022mailto:hc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u0022\u003Ehc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u003C\/a\u003E\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00510#PGR","text":"Plan de gestion des risques"},"various_dates":"False"},{"id":"31","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-03-11","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/renseignements-cliniques.canada.ca\/ci-rc\/conditions?id=244906","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"32","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-05","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit. Le statut des conditions sera mis \u00e0 jour sur une base r\u00e9guli\u00e8re.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-autorisation.pdf","text":"Conditions de l\u2019autorisation"},"updated_date":"2021-05-05","various_dates":"False"},{"id":"33","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis publics et les communications des risques li\u00e9s aux produits de sant\u00e9 sont deux moyens par lesquels Sant\u00e9 Canada communique les questions de s\u00e9curit\u00e9. Ils sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Pfizer-BioNTech%20COVID-19%20Vaccine%22%20OU%20%22tozinameran%22","text":"Avis publics et communications des risques"},"various_dates":"False"},{"id":"38","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-26","description":"\u003Cp\u003ELes \u00e9tapes de l\u2019administration du vaccin contre la COVID-19 de Pfizer-BioNTech. Votre guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-etapes-administration.pdf","text":"Conservation, manipulation et administration"},"updated_date":"2021-03-26","various_dates":"False"},{"id":"73","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-16","description":"\u003Cp\u003EInformations destin\u00e9es aux professionnels de la sant\u00e9 sur l\u0027utilisation de seringues et d\u0027aiguilles \u00e0 faible volume mort.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-renseignements-faible-volume-mort.pdf","text":"Guide d\u0027administration pour les seringues et les aiguilles \u00e0 faible volume mort"},"various_dates":"False"},{"id":"39","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-26","description":"\u003Cp\u003EDirectives d\u2019exp\u00e9dition et de manipulation. Pour vous assurer que les contr\u00f4les appropri\u00e9s sont mis en place, veuillez consulter la fiche des donn\u00e9es de s\u00e9curit\u00e9 de la glace s\u00e8che avant d\u2019acc\u00e9der au contenu du conteneur d\u2019exp\u00e9dition isotherme, et consultez votre service de sant\u00e9 et s\u00e9curit\u00e9 au travail.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-contre-la-covid-19-de-pfizer-biontech-directives-expedition-manipulation.pdf","text":"Directives d\u2019exp\u00e9dition et de manipulation"},"updated_date":"2021-03-26","various_dates":"False"}]},{"nid":"15","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/covid-19-vaccine-moderna\/details-produit","title":"COVID-19 Vaccine Moderna (ARNm-1273 SRAS-CoV-2)","brand_name":"COVID-19 Vaccine Moderna","ingredient":"ARNm-1273 SRAS-CoV-2","company_name":"ModernaTX, Inc.","field_product_type":"Vaccin","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"2020-12-23","language":"Fran\u00e7ais","resources":[{"id":"53","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-05-11","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/covid-19-vaccine-moderna-fr.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-05-11","various_dates":"False"},{"id":"54","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-11","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EPartie II : Renseignements scientifiques\u003C\/li\u003E\n\t\u003Cli\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-pm-fr.pdf","text":"Monographie de produit"},"updated_date":"2021-05-11","various_dates":"False"},{"id":"55","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-22","description":"\u003Cp\u003E\u00c9tiquettes unilingues anglaises de la fiole et de la bo\u00eete du vaccin de Moderna contre la COVID-19. Ces \u00e9tiquettes sont utilis\u00e9es pour l\u0027approvisionnement initial en vaccins.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-etiquette.pdf","text":"\u00c9tiquette provisioire du produit"},"updated_date":"2021-02-22","various_dates":"False"},{"id":"116","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-12","description":"\u003Cp\u003E\u00c9tiquettes de r\u00e9f\u00e9rence canadiennes pour les \u00e9tiquettes des flacons et des cartons. Ces \u00e9tiquettes fournissent des informations sp\u00e9cifiques au Canada en fran\u00e7ais et en anglais et peuvent \u00eatre utilis\u00e9es comme r\u00e9f\u00e9rence jusqu\u0027\u00e0 ce que le fabricant les adopte sur le flacon et le carton du produit sp\u00e9cifique au Canada.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-canadian-label.pdf","text":"\u00c9tiquettes de r\u00e9f\u00e9rence canadiennes"},"various_dates":"False"},{"id":"56","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-12-23","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00736","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"various_dates":"False"},{"id":"57","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00511","text":"Sommaire des motifs de d\u00e9cision"},"updated_date":"2021-03-19","various_dates":"False"},{"id":"69","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00511","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"updated_date":"2021-04-19","various_dates":"False"},{"id":"66","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes donn\u00e9es sur les effets secondaires suivant l\u2019immunisation. Un effet secondaire est un incident m\u00e9dical qui peut suivre l\u2019immunisation. La cause n\u2019est pas n\u00e9cessairement li\u00e9e au vaccin.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/sante-infobase.canada.ca\/covid-19\/securite-vaccins\/","text":"Effets secondaires suivant l\u2019immunisation"},"various_dates":"True"},{"id":"59","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-02","description":"\u003Cp\u003ELe plan de gestion des risques de la compagnie comporte :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003ELes risques connus et potentiels\u003C\/li\u003E\n\t\u003Cli\u003ELe plan de surveillance de la compagnie, y compris le recueil des renseignements suppl\u00e9mentaires sur l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9\u003C\/li\u003E\n\t\u003Cli\u003EToute mesure de la part de la compagnie pour att\u00e9nuer les risques associ\u00e9s au produit\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003EEn cliquant sur le lien, vous acc\u00e9dez \u00e0 un r\u00e9sum\u00e9 du plan de gestion des risque. Vous pouvez obtenir la version la plus r\u00e9cente (disponible uniquement dans la langue dans laquelle elle a \u00e9t\u00e9 soumise) en posant une demande par courriel \u00e0 \u003Ca href=\u0022mailto:hc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u0022\u003Ehc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u003C\/a\u003E\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00511#PGR","text":"Plan de gestion des risques"},"various_dates":"False"},{"id":"60","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-03-02","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/renseignements-cliniques.canada.ca\/ci-rc\/conditions?id=244946","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"61","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-07","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit. Le statut des conditions sera mis \u00e0 jour sur une base r\u00e9guli\u00e8re.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/vaccin-de-moderna-contre-la-covid-19-autorisation.pdf","text":"Conditions de l\u2019autorisation"},"updated_date":"2021-05-07","various_dates":"False"},{"id":"62","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis publics et les communications des risques li\u00e9s aux produits de sant\u00e9 sont deux moyens par lesquels Sant\u00e9 Canada communique les questions de s\u00e9curit\u00e9. Ils sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=%22Vaccin%20de%20Moderna%20contre%20la%20COVID-19%22%20OU%20%22ARNm-1273%20SRAS-CoV-2%22","text":"Avis publics et communications des risques"},"various_dates":"True"},{"id":"63","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-26","description":"\u003Cp\u003ELes \u00e9tapes de l\u2019administration du vaccin de Moderna contre la COVID-19. Votre guide pour assurer la conservation, la manipulation et l\u2019administration ad\u00e9quate du vaccin de Moderna contre la COVID-19.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-entreposage-manipulation.pdf","text":"Conservation, manipulation et administration"},"updated_date":"2021-02-26","various_dates":"False"}]},{"nid":"8","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/bamlanivimab\/details-produit","title":"Bamlanivimab (bamlanivimab)","brand_name":"Bamlanivimab","ingredient":"bamlanivimab","company_name":"Eli Lilly Canada Inc","field_product_type":"Traitement","status":"Autoris\u00e9 par arr\u00eat\u00e9 d\u0026#039;urgence","date_of_approval":"2020-11-20","language":"Fran\u00e7ais","resources":[{"id":"17","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-16","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/bamlanivimab-fr.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-04-16","various_dates":"False"},{"id":"18","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-16","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/bamlanivimab-pm1-fr.pdf","text":"Monographie de produit"},"updated_date":"2021-04-16","various_dates":"False"},{"id":"19","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-10-12","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detailTwo.html?linkID=RDS00719","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"various_dates":"False"},{"id":"20","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-01-08","description":"\u003Cp class=\u0022MsoNormal\u0022\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication).\u003C\/span\u003E\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00512","text":"Sommaire des motifs de d\u00e9cision"},"various_dates":"False"},{"id":"71","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00512","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"updated_date":"2021-04-19","various_dates":"False"},{"id":"21","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-01-04","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/renseignements-cliniques.canada.ca\/ci-rc\/conditions?id=244947","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"22","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-12-23","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/bamlanivimab-autorisation.pdf","text":"Conditions de l\u2019autorisation"},"various_dates":"False"},{"id":"23","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=bamlanivimab%20OU%20Bamlanivimab","text":"Avis"},"various_dates":"True"}]},{"nid":"9","view_node":"https:\/\/vaccin-covid-stage.hpfb-dgpsa.ca\/veklury\/details-produit","title":"Veklury (remd\u00e9sivir)","brand_name":"Veklury","ingredient":"remd\u00e9sivir","company_name":"Gilead Sciences Canada Inc","field_product_type":"Traitement","status":"Autoris\u00e9","date_of_approval":"2020-07-27","language":"Fran\u00e7ais","resources":[{"id":"5","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003ERenseignements sur le produit y compris pour quoi on s\u2019en sert, la posologie, les mises en garde, l\u2019usage correct et les effets secondaires. Ce sommaire ne comportera pas toute l\u2019information pertinente sur le produit. Veuillez contacter votre professionnel de la sant\u00e9 pour toute question sur le produit.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/veklury-fr.html","text":"Renseignements \u00e0 l\u0027intention des consommateurs"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"6","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-07-27","description":"\u003Cp\u003ELa monographie de produit est un document scientifique qui d\u00e9crit les propri\u00e9t\u00e9s, les affirmations, les indications et les conditions d\u0027utilisation du produit, et qui contient tout autre renseignement pouvant \u00eatre requis pour l\u2019utilisation optimale, s\u00e9curitaire et efficace.\u003C\/p\u003E\n\n\u003Cp\u003EUne monographie de produit comporte trois parties :\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie I : Renseignements pour le professionnel de la sant\u00e9\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003EPartie II : Renseignements scientifiques\u003C\/p\u003E\n\t\u003C\/li\u003E\n\t\u003Cli\u003E\n\t\u003Cp\u003ERenseignements sur le m\u00e9dicament pour le patient\u003C\/p\u003E\n\t\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/veklury-pm1-fr.pdf","text":"Monographie de produit"},"various_dates":"False"},{"id":"8","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-12-02","description":"\u003Cp\u003ELe sommaire de d\u00e9cision r\u00e9glementaire explique la d\u00e9cision de Sant\u00e9 Canada face au produit pour lequel une autorisation de mise en march\u00e9 est demand\u00e9e. Le sommaire de d\u00e9cision r\u00e9glementaire comporte le but de la pr\u00e9sentation et le motif de la d\u00e9cision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-decision-reglementaire-detail.html?linkID=RDS00669","text":"Sommaire de d\u00e9cision r\u00e9glementaire"},"various_dates":"False"},{"id":"14","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-12-02","description":"\u003Cp class=\u0022MsoNormal\u0022\u003E\u003Cspan lang=\u0022FR-CA\u0022 style=\u0022mso-ansi-language:FR-CA\u0022 xml:lang=\u0022FR-CA\u0022\u003ELe sommaire des motifs de d\u00e9cision explique les raisons pour lesquelles un produit a re\u00e7u une autorisation de vente au Canada. Le document comprend les consid\u00e9rations portant sur la r\u00e9glementation, l\u2019innocuit\u00e9, l\u2019efficacit\u00e9 et la qualit\u00e9 (sur le plan de la chimie et de la fabrication). \u003C\/span\u003E\u003C\/p\u003E\n","resource_link":{"url":"\/info\/sommaire-motif-decision-detailTwo.html?linkID=SBD00491","text":"Sommaire des motifs de d\u00e9cision"},"various_dates":"False"},{"id":"123","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-09","description":"\u003Cp\u003EUn resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9 compl\u00e8te d\u0027autres informations li\u00e9es \u00e0 l\u0027innocuit\u00e9 afin d\u0027aider les Canadiens \u00e0 prendre des d\u00e9cisions \u00e9clair\u00e9es au sujet du l\u0027utilisation des produits de sant\u00e9. Chaque r\u00e9sum\u00e9 pr\u00e9sente les donn\u00e9es \u00e9valu\u00e9es dans le cadre de l\u2019examen de Sant\u00e9 Canada, les conclusions et les mesures prises par Sant\u00e9 Canada, le cas \u00e9ch\u00e9ant.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/resume-examen-innocuite-detail.html?linkID=SSR00264","text":"Resum\u00e9 de l\u2019examen de l\u0027innocuit\u00e9"},"various_dates":"False"},{"id":"72","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003ELe tableau des activit\u00e9s postautorisation comprend de brefs r\u00e9sum\u00e9s des activit\u00e9s qui ont lieu apr\u00e8s l\u0027approbation du produit. Il est mis \u00e0 jour chaque mois.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/tableau-activites-postautorisation.html?linkID=SBD00491","text":"Tableau des activit\u00e9s postautorisation (TAPA)"},"updated_date":"2021-04-19","various_dates":"False"},{"id":"10","bundle":"vaccine_resources","audience":["Researchers"],"date":"2020-10-30","description":"\u003Cp\u003ESuite \u00e0 l\u2019ach\u00e8vement de l\u2019examen r\u00e9glementaire, les renseignements cliniques d\u00e9pos\u00e9s dans le cadre de la pr\u00e9sentation sont rendus accessibles au public pour des fins non commerciales.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=240551","text":"Renseignements cliniques"},"various_dates":"False"},{"id":"15","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-07-27","description":"\u003Cp\u003EPour les autorisations pour la COVID-19, Sant\u00e9 Canada peut imposer des conditions sp\u00e9cifiques \u00e0 l\u2019autorisation. Ceci permet \u00e0 Sant\u00e9 Canada de continuer de recueillir de renseignements sur l\u0027innocuit\u00e9, l\u0027efficacit\u00e9 et\/ou la qualit\u00e9 du produit, tandis que des \u00e9tudes suppl\u00e9mentaires se poursuivent.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/avis-conformite\/conditions\/avis-admissibilite-veklury-240551.html","text":"Conditions de l\u2019autorisation"},"various_dates":"False"},{"id":"7","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003ELes avis sont publi\u00e9s lorsque Sant\u00e9 Canada a des mises \u00e0 jours ou d\u2019autres renseignements importants \u00e0 communiquer, tels que l\u2019information sur les nouvelles approbations, les p\u00e9nuries, les mises \u00e0 jour de l\u0027\u00e9tiquette ou les risques.\u003C\/p\u003E\n\n\u003Cp\u003ELorsque vous cliquez sur le lien, vous extrairez tout avis \u00e9mis par Sant\u00e9 Canada sur le produit. Si aucun avis n\u2019a \u00e9t\u00e9 \u00e9mis, aucun r\u00e9sultat ne para\u00eetra.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/fr?search_text_1=remdesivir%20OU%20veklury","text":"Avis"},"various_dates":"True"},{"id":"13","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2020-11-26","description":"\u003Cp\u003EUne mise \u00e0 jour de Sant\u00e9 Canada sur la surveillance continue de l\u0027utilisation du remd\u00e9sivir pour la COVID-19.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/covid19-industrie\/medicaments-vaccins-traitements\/mise-a-jour-remdesivir.html","text":"Mise \u00e0 jour sur le remd\u00e9sivir : surveillance continue"},"various_dates":"False"}]},{"nid":"16","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/pfizer-biontech-covid-19-vaccine\/product-details","title":"Pfizer-BioNTech COVID-19 Vaccine (tozinameran)","brand_name":"Pfizer-BioNTech COVID-19 Vaccine","ingredient":"tozinameran","company_name":"BioNTech Manufacturing GmbH","field_product_type":"Vaccine","status":"Authorized By Interim Order","date_of_approval":"2020-12-09","language":"English","resources":[{"id":"27","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-05-05","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pfizer-biontech-covid-19-vaccine-en.html","text":"Consumer Information"},"updated_date":"2021-05-05","various_dates":"False"},{"id":"28","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-05","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n","resource_link":{"url":"\/info\/pdf\/pfizer-biontech-covid-19-vaccine-pm1-en.pdf","text":"Product Monograph"},"updated_date":"2021-05-05","various_dates":"False"},{"id":"40","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-09","description":"\u003Cp\u003EVial and carton labels for Pfizer-BioNTech COVID-19 Vaccine with English-only labelling. These labels are used for the initial supply of vaccine.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/pfizer-biontech-covid-19-label.pdf","text":"Interim Product Label"},"various_dates":"False"},{"id":"29","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-12-09","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00730","text":"Regulatory Decision Summary"},"various_dates":"False"},{"id":"128","bundle":"vaccine_resources","audience":["Consumers"],"date":"2021-05-05","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00802","text":"Regulatory Decision Summary (ages 12-15)"},"various_dates":"False"},{"id":"30","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00510","text":"Summary Basis of Decision"},"updated_date":"2021-03-19","various_dates":"False"},{"id":"70","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-21","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00510","text":"Post-Authorization Activity Table (PAAT)"},"updated_date":"2021-05-21","various_dates":"False"},{"id":"67","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/","text":"Adverse Events Following Immunization"},"various_dates":"True"},{"id":"35","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-02-19","description":"\u003Cp\u003EThe Company\u2019s\u00a0Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003EClicking on the link will take you to a summary of the Risk Management Plan. The Risk Management Plan may be updated following authorization. The most recent version (available only in the language in which it was submitted) can be requested by email to \u003Ca href=\u0022mailto:hc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u0022\u003Ehc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u003C\/a\u003E\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00510#RMP","text":"Risk Management Plan"},"various_dates":"False"},{"id":"31","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-03-11","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=244906","text":"Clinical Information"},"various_dates":"False"},{"id":"32","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-05","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product. The status of the terms and conditions will be updated on a regular basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/pfizer-biontech-covid-19-vaccine-authorisation.pdf","text":"Authorization Terms \u0026 Conditions"},"updated_date":"2021-05-05","various_dates":"False"},{"id":"33","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EPublic Advisories and Health Product Risk Communications are two ways that Health Canada communicates safety issues. They are published when Health Canada has important updates or other information to share about the product, such as new approvals, information on shortages, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories and risk communications that Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Pfizer-BioNTech%20COVID-19%20Vaccine%22%20OR%20%22tozinameran%22","text":"Public Advisories and Risk Communications"},"various_dates":"True"},{"id":"38","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-26","description":"\u003Cp\u003EThe steps to Pfizer-BioNTech COVID-19 Vaccination. Your guide to proper storage, handling, and administration of the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/pfizer-biontech-covid-19-steps-leaflet-en.pdf","text":"Storage, handling, and administration"},"updated_date":"2021-03-26","various_dates":"False"},{"id":"73","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-16","description":"\u003Cp\u003EInformation for healthcare professionals about the use of low dead-volume syringes and needles.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/pfizer-biontech-covid-19-information-low-dead-volume.pdf","text":"Administration Guide for low dead-volume syringes and needles"},"various_dates":"False"},{"id":"39","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-26","description":"\u003Cp\u003EShipping and handling guidelines. To ensure appropriate controls are in place, review the enclosed dry ice safety data sheet before accessing the contents from the thermal shipping container and consult with your occupational health department.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/pfizer-biontech-covid-19-shipping-handling-guidelines-en.pdf","text":"Shipping and handling guidelines"},"updated_date":"2021-03-26","various_dates":"False"}]},{"nid":"15","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/covid-19-vaccine-moderna\/product-details","title":"COVID-19 Vaccine Moderna (mRNA-1273 SARS-CoV-2)","brand_name":"COVID-19 Vaccine Moderna ","ingredient":"mRNA-1273 SARS-CoV-2","company_name":"ModernaTX, Inc.","field_product_type":"Vaccine","status":"Authorized By Interim Order","date_of_approval":"2020-12-23","language":"English","resources":[{"id":"53","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-05-11","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/covid-19-vaccine-moderna-en.html","text":"Consumer Information"},"updated_date":"2021-05-11","various_dates":"False"},{"id":"54","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-11","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-pm-en.pdf","text":"Product Monograph"},"updated_date":"2021-05-11","various_dates":"False"},{"id":"55","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-02-22","description":"\u003Cp\u003EVial and carton labels for Moderna COVID-19 Vaccine with English-only labelling. These labels are used for the initial supply of vaccine.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-label.pdf","text":"Interim Product Label"},"updated_date":"2021-02-22","various_dates":"False"},{"id":"116","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2021-03-12","description":"\u003Cp\u003EThe Canadian reference labels for the vial and carton labels. These labels provide information specific to Canada in both French and English and can be used as reference until the manufacturer implements them on the Canadian-specific product vial and carton.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-canadian-label.pdf","text":"Canadian Reference Label"},"various_dates":"False"},{"id":"56","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-12-23","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The Regulatory Decision Summary includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00736","text":"Regulatory Decision Summary"},"various_dates":"False"},{"id":"57","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-19","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00511","text":"Summary Basis of Decision"},"updated_date":"2021-03-19","various_dates":"False"},{"id":"69","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00511","text":"Post-Authorization Activity Table (PAAT) "},"updated_date":"2021-04-19","various_dates":"False"},{"id":"66","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EInformation about adverse events following immunization. An adverse event is a medical incident that may occur following immunization. The cause is not necessarily related to the vaccine.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/","text":"Adverse Events Following Immunization"},"various_dates":"True"},{"id":"59","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-03-02","description":"\u003Cp\u003EThe Company\u2019s\u00a0Risk Management Plan describes:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EKnown and potential safety issues\u003C\/li\u003E\n\t\u003Cli\u003EThe company\u2019s monitoring plan, including plans for collection of additional safety and effectiveness information\u003C\/li\u003E\n\t\u003Cli\u003EAny measures that will be put in place to minimize risks associated with the product.\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003EClicking on the link will take you to a summary of the Risk Management Plan. The Risk Management Plan may be updated following authorization. The most recent version (available only in the language in which it was submitted) can be requested by email to \u003Ca href=\u0022mailto:hc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u0022\u003Ehc.mbbnhpb.rpm-gpr.bpbbsnc.sc@canada.ca\u003C\/a\u003E\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00511#RMP","text":"Risk Management Plan"},"various_dates":"False"},{"id":"60","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-03-02","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=244946","text":"Clinical Information"},"various_dates":"False"},{"id":"61","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-05-07","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product. The status of the terms and conditions will be updated on a regular basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/moderna-covid-19-vaccine-authorisation.pdf","text":"Authorization Terms \u0026 Conditions"},"updated_date":"2021-05-07","various_dates":"False"},{"id":"62","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EPublic Advisories and Health Product Risk Communications are two ways that Health Canada communicates safety issues. They are published when Health Canada has important updates or other information to share about the product, such as new approvals, information on shortages, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories and risk communications that Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=%22Moderna%20COVID-19%20Vaccine%22%20OR%20%22mRNA-1273%20SARS-CoV-2%22","text":"Public Advisories and Risk Communications"},"various_dates":"True"},{"id":"63","bundle":"vaccine_resources","audience":["Health Care Professionals"],"date":"2020-02-26","description":"\u003Cp\u003EThe steps to Moderna COVID-19 Vaccination. Your guide to proper storage, handling, and administration for the Moderna COVID-19 Vaccine.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/covid-19-vaccine-moderna-storage-handling.pdf","text":"Storage, handling, and administration"},"updated_date":"2021-02-26","various_dates":"False"}]},{"nid":"9","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/veklury\/product-details","title":"Veklury (remdesivir)","brand_name":"Veklury","ingredient":"remdesivir","company_name":"Gilead Sciences Canada Inc","field_product_type":"Treatment","status":"Authorized","date_of_approval":"2020-07-27","language":"English","resources":[{"id":"5","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-26","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the product. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/veklury-en.html","text":"Consumer Information"},"updated_date":"2021-04-26","various_dates":"False"},{"id":"6","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-07-27","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/veklury-pm1-en.pdf","text":"Product Monograph"},"various_dates":"False"},{"id":"8","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-07-27","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detail.html?linkID=RDS00669","text":"Regulatory Decision Summary"},"various_dates":"False"},{"id":"14","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-12-02","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00491","text":"Summary Basis of Decision"},"various_dates":"False"},{"id":"123","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-09","description":"\u003Cp\u003EA Summary Safety Review complements other safety related information to help Canadians make informed decisions about their use of health products. Each summary outlines what was assessed in Health Canada\u2019s review, what was found and what action was taken by Health Canada, if any.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-safety-review-detail.html?linkID=SSR00264","text":"Summary Safety Review"},"various_dates":"False"},{"id":"72","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00491","text":"Post-Authorization Activity Table (PAAT) "},"updated_date":"2021-04-19","various_dates":"False"},{"id":"10","bundle":"vaccine_resources","audience":["Researchers"],"date":"2020-10-30","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=240551","text":"Clinical Information"},"various_dates":"False"},{"id":"15","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-07-27","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/qualifying-notice-veklury-240551.html","text":"Authorization Terms \u0026 Conditions"},"various_dates":"False"},{"id":"7","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=Remdesivir%20OR%20Veklury","text":"Advisories"},"various_dates":"True"},{"id":"13","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2020-11-26","description":"\u003Cp\u003EAn update from Health Canada on the continued monitoring of the use of remdesivir for COVID-19.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/remdesivir-update.html","text":"Update on remdesivir: continued monitoring"},"various_dates":"False"}]},{"nid":"8","view_node":"https:\/\/covid-vaccine-stage.hpfb-dgpsa.ca\/bamlanivimab\/product-details","title":"Bamlanivimab (bamlanivimab)","brand_name":"Bamlanivimab","ingredient":"bamlanivimab","company_name":"Eli Lilly Canada Inc","field_product_type":"Treatment","status":"Authorized By Interim Order","date_of_approval":"2020-11-20","language":"English","resources":[{"id":"17","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals"],"date":"2021-04-16","description":"\u003Cp\u003EInformation about the product including what the product is used for, dosage, warnings, proper use and side effects.\u00a0 This summary will not tell you everything about the drug. Contact your healthcare professional if you have any questions about the product.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/bamlanivimab-en.html","text":"Consumer Information"},"updated_date":"2021-04-16","various_dates":"False"},{"id":"18","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-16","description":"\u003Cp\u003EThe Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use.\u003C\/p\u003E\n\n\u003Cp\u003EThe Product Monograph includes three sections:\u003C\/p\u003E\n\n\u003Cul\u003E\n\t\u003Cli\u003EPart I: Health Professional Information;\u003C\/li\u003E\n\t\u003Cli\u003EPart II: Scientific Information; and\u003C\/li\u003E\n\t\u003Cli\u003EPatient Medication Information\u003C\/li\u003E\n\u003C\/ul\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/bamlanivimab-pm1-en.pdf","text":"Product Monograph"},"updated_date":"2021-04-16","various_dates":"False"},{"id":"19","bundle":"vaccine_resources","audience":["Consumers"],"date":"2020-10-12","description":"\u003Cp\u003EThe Regulatory Decision Summary explains Health Canada\u2019s decision for the product seeking market authorization. The RDS includes the purpose of the submission and the reason for the decision.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00719","text":"Regulatory Decision Summary"},"various_dates":"False"},{"id":"20","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-01-08","description":"\u003Cp\u003EThe Summary Basis of Decision explains why the product was approved for sale in Canada. The document includes regulatory, safety, effectiveness and quality (in terms of chemistry and manufacturing) considerations.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/summary-basis-decision-detailTwo.html?linkID=SBD00512","text":"Summary Basis of Decision"},"various_dates":"False"},{"id":"71","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2021-04-19","description":"\u003Cp\u003EThe Post Authorization Activity Table includes brief summaries of the activities that occur after the approval of the product. It is updated on a monthly basis.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/post-authorization-activity-table.html?linkID=SBD00512","text":"Post-Authorization Activity Table (PAAT) "},"updated_date":"2021-04-19","various_dates":"False"},{"id":"21","bundle":"vaccine_resources","audience":["Researchers"],"date":"2021-01-04","description":"\u003Cp\u003EAfter Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/clinical-information.canada.ca\/ci-rc\/terms?id=244947","text":"Clinical Information"},"various_dates":"False"},{"id":"22","bundle":"vaccine_resources","audience":["Health Care Professionals","Researchers"],"date":"2020-12-23","description":"\u003Cp\u003EFor COVID-19 authorizations, Health Canada can impose specific terms and conditions on the authorization. This allows Health Canada to continue to gather information on the safety, effectiveness and\/or quality of the product as more studies are completed.\u003C\/p\u003E\n","resource_link":{"url":"\/info\/pdf\/bamlanivimab-authorisation.pdf","text":"Authorization Terms \u0026 Conditions"},"various_dates":"False"},{"id":"23","bundle":"vaccine_resources","audience":["Consumers","Health Care Professionals","Researchers"],"description":"\u003Cp\u003EAdvisories are published when Health Canada has important updates or other information to share about the product, such as information on new approvals, shortages, labelling updates, or risks.\u003C\/p\u003E\n\n\u003Cp\u003EClicking the link will retrieve any advisories Health Canada has issued about the product. If no advisories have been issued, no results will be returned.\u003C\/p\u003E\n\n\u003Cp\u003E\u00a0\u003C\/p\u003E\n","resource_link":{"url":"https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/search-recherche\/result-resultat\/en?search_text_1=Bamlanivimab%20OR%20bamlanivimab","text":"Advisories"},"various_dates":"True"}]}]